The field of drug discovery is witnessing a revolutionary shift with the advent of Proteolysis Targeting Chimeras (PROTACs). This innovative therapeutic strategy is redefining how we approach the degradation of proteins, especiallyRead More…
Over the past two decades, protein-targeting degradation technologies (TPD), epitomized by PROTAC (proteolysis targeting chimera), have undergone rapid development and are considered one of the most promising breakthrough technologies for tackling difficult-to-drugRead More…
Targeted protein degradation (TPD) primarily degrades target proteins through the ubiquitin-proteasome and lysosome, and according to the specific mechanism of action, it can be further subdivided into nearly 10 different technical routes,Read More…
N 6-methyladenosine (m6A) methylation is the most abundant type of RNA modification, primarily catalyzed by the METTL3-METTL14 methyltransferase complex (MTC). This complex includes the core catalytic proteins METTL3 and METTL14, as wellRead More…
In Alzheimer’s disease, fibrous tau pathology accumulates and spreads in the brain, leading to synaptic loss. Researchers studying mouse models have found that tau protein can spread from presynaptic to postsynaptic synapses,Read More…
PROTAC uses the natural mechanism of protein degradation in cells, that is, the ubiquitin-protease system, to induce targeted protein degradation. Compared with traditional small molecular inhibitors used in cancer therapy, PROTAC hasRead More…
Recently, the Li Zigang and Yin Feng research group of Shenzhen Graduate School of Peking University published a research paper entitled “Targeted biomolecule regulation platform: a Split-and-Mix PROTAC approach” in Journal ofRead More…
Protein degradation targeted chimera (PROTAC) can efficiently degrade disease-causing proteins to treat varieties of diseases and has been widely investigated by global researchers. Despite of its promising prospects, the pharmacokinetic behavior ofRead More…
Acute lymphoblastic leukemia (ALL) is a common disease. B-ALL and T-ALL account for 85% and 15% of the two lymphatic lineages of ALL, respectively, but patients with T-ALL have poor life qualityRead More…
PROTAC consists of a flexible linker conjugating the protein of interest (POI) ligand and an E3 ligase ligand. Its action mechanism makes use of the mechanism of protein degradation induced by theRead More…